Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance

Stock Information for Co-Diagnostics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Co-Diagnostics Inc.

Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast
Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit
Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025
Co-Diagnostics, Inc. to Exhibit at BioUtah's 2025 Life Sciences Day on the Hill
Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025
Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility
Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.